Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
autologous CD133+ cells
- Development stage
- Phase 4
- Lead developer
- Miltenyi Biotec
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intraportal, Intracoronary, Intrauterine, Intralesional Injection
01
Overview
Autologous CD133+ cells are a cell-based therapeutic consisting of progenitor cells isolated from a patient's own bone marrow. CD133 (prominin-1) is a glycoprotein marker for primitive hematopoietic stem cells and endothelial progenitor cells. In clinical applications for cardiovascular disease, these cells are typically enriched using magnetic cell separation technology (such as the CliniMACS system) and then delivered via intramyocardial injection. The therapeutic rationale is that these cells promote neoangiogenesis and myocardial repair through paracrine signaling and potential differentiation into vascular or cardiac lineages, thereby improving cardiac function in patients with chronic ischemic heart disease or following myocardial infarction.
- Other names
- autologous CD133+ bone marrow stem cellsCD133+ bone marrow-derived stem cellsautologous CD133+ bone marrow-derived stem cells
Beyond the preview
Go deeper on autologous CD133+ cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on autologous CD133+ cells.